| Name | Title | Contact Details |
|---|
Empowering people worldwide to connect, create and earn in virtual worlds. Together Labs is the company behind VCOIN, IMVU and WithMe and is based in Palo Alto, California.
SnippetSentry is a company that provides a customizable platform, SnippetExchange, to securely capture, observe, engage, and dispatch mobile data transmissions such as iMessage, SMS/MMS, and WhatsApp, to strengthen the enterprise security posture.
Duos Technologies Group, Inc. (Nasdaq: DUOT), based in Jacksonville, Florida, through its wholly owned subsidiary, Duos Technologies, Inc. designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics, intermodal and Government customers that improve safety, streamline operations, and reduce costs. Since our inception in 1990, Duos Technologies, Inc. (Duos) has provided a broad variety of sophisticated, technology-based applications to a growing range of clientele. We specialize in automated systems with an emphasis on Machine Vision & Artificial Intelligence, vision based analytical technology solutions, and integrated smart Command & Control centers that combine both new and existing equipment and a broad range of smart sensor systems. Our combined team expertise includes subject matter experts (with years of practical experience) in the diverse fields of mechanical, electrical, chemical, industrial, electronic, and computer engineering, IT, procurement, project management, and construction management. We start with a customer`s rough concept or requirement, and leverage our unique synergy to define, create, enable, and implement a solution to meet those requirements. Our organizational structure and company culture encourage our team members to respond and interact innovatively and proactively to the needs of our customers. Most companies drive the customer toward a cookie‐cutter, one size fits all solution – this is the Duos point of difference. We have a richness of expertise, experience, partnerships, and resources to provide one-stop- shop solutions that specifically meet the needs of our customers.
Ambition is at the very core of success and extraordinary accomplishment. Given the right direction it can become a constructive force turning eager desires into reality. It gives the necessary thrust that drives you through the thick and thin and lead...
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.